ReviewStem cells international2019
Pancreatic Progenitors and Organoids as a Prerequisite to Model Pancreatic Diseases and Cancer.
Review in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights.Cytotherapy · 2025Review
- Generation of human iPSC-derived pancreatic organoids to study pancreas development and disease.F1000Research · 2025Article
- Time-efficient strategies in human iPS cell-derived pancreatic progenitor differentiation and cryopreservation: advancing towards practical applications.Stem cell research & therapy · 2024Article
- Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis.World journal of gastrointestinal oncology · 2024Article
- Article
- Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells.Cell stem cell · 2021Article
- Organoids: a novel modality in disease modeling.Bio-design and manufacturing · 2021Review
- The Potential of Induced Pluripotent Stem Cells to Treat and Model Alzheimer's Disease.Stem cells international · 2021Review
- Organoids in Translational Oncology.Journal of clinical medicine · 2020Review
- Modeling endodermal organ development and diseases using human pluripotent stem cell-derived organoids.Journal of molecular cell biology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their unique capacity to stepwise differentiate towards any particular cell type in an adult organism. Pluripotent stem cells provide a beneficial platform to model hereditary diseases and even cancer development. While the incidence of pancreatic diseases such as diabetes and pancreatitis is increasing, the understanding of the underlying pathogenesis of particular diseases remains limited. Only a few recent publications have contributed to the characterization of human pancreatic development in the fetal stage. Hence, most knowledge of pancreatic specification is based on murine embryology. Optimizing and understanding current
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.